Systemic glucocorticoids confound SARS-CoV-2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al

Arthritis Rheumatol. 2022 Dec;74(12):2042-2043. doi: 10.1002/art.42303. Epub 2022 Oct 17.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Autoimmune Diseases* / drug therapy
  • Biological Products* / therapeutic use
  • COVID-19*
  • Glucocorticoids / therapeutic use
  • Humans
  • SARS-CoV-2

Substances

  • Glucocorticoids
  • Biological Products